article thumbnail

Disaster preparedness, What we have learned from COVID 19 pandemic [COVID-19]

Annals of Family Medicine

Context: Despite a joint recommendation in 2003 by the AAMC and CDC that bioterrorism and mass-casualty training be included in the medical school curriculum, few medical schools have incorporated formal disaster training. Regarding clinical education changes since March 2020, 47% (n=16) were satisfied.

article thumbnail

Cancer Doesn't Discriminate. or Does It? Dr. Rebecca Redman

Louisville Lectures

After, she examines the role of clinical trials in challenging status quo. She graduated from the University of Wisconsin School of Medicine & Public Health in 2003. Watch on YouTube Listen as a Podcast Watch more lectures about Internal Medicine Rebecca Redman, M.D.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating the Quademic: Clinical Differentiation of Influenza, RSV, COVID-19, and Norovirus in Pediatric Emergency Care

PEMBlog

Differentiating these pathogens based on clinical presentation is crucial for targeted management, minimizing unnecessary diagnostic tests, and optimizing healthcare resources. Secondary bacterial pneumonia: Characterized by clinical deterioration after an initial period of improvement.

Clinic 52
article thumbnail

Episode 176: Antiracism in Medicine Series – Episode 8 – Towards Justice and Race Conscious Medicine

The Clinical Problem Solvers

The answer to this question may not be easily answered and may not always be found in the clinical setting. The use of race is based on a false/biological concept of race AND many studies show that this can harm patients ( i.e. clinical resources are withheld based on results of algorithm).

article thumbnail

Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities

FDA Law Blog

Also part of FDA’s FY2023 guidance document plan is a retrospective review of guidance documents issued in 1993, 2003, and 2013. FDA’s retrospective review of the 2003 guidance documents will include user labeling for devices that contain natural rubber and premarket approval application modular review.

Medical 52
article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog

The closest FDA has come is in a 2003 preamble noting that patents that claim finished dosage forms—which can include “metered aerosols, capsules, metered sprays, gels, and pre-filled drug delivery systems”—should be listed in the Orange Book, suggesting that a patent that claims both the drug substance and the delivery device should be listed.

article thumbnail

PEMPix 2023 Online Case 3: The Only Thing We Have to Fear

PEMBlog

Clinical features of neonatal toxic shock syndrome-like exanthematous disease emerging in Japan. [link] Takahashi, N., Nishida, H., Yamasaki, C., Takahashi, K., Y., & Uchiyama, T. The Journal of infection, 59(3), 194–200. link] Takahashi N. Neonatal toxic shock syndrome-like exanthematous disease (NTED).